Egle therapeutics identifies first novel regulatory t-cell targets in research alliance with takeda

Paris--(business wire)--egle therapeutics sas (egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory t-cells (tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with takeda pharmaceutical company limited (“takeda”). in the course of the strategic research alliance that was announced in june 2020, egle will validate novel tumor-infil
TAK Ratings Summary
TAK Quant Ranking